367 related articles for article (PubMed ID: 33545157)
1. COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes.
Al-Hatamleh MAI; Hatmal MM; Alshaer W; Rahman ENSEA; Mohd-Zahid MH; Alhaj-Qasem DM; Yean CY; Alias IZ; Jaafar J; Ferji K; Six JL; Uskoković V; Yabu H; Mohamud R
Eur J Pharmacol; 2021 Apr; 896():173930. PubMed ID: 33545157
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: Progress in diagnostics, therapy and vaccination.
Liu X; Liu C; Liu G; Luo W; Xia N
Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 challenges and its therapeutics.
Rehman SU; Rehman SU; Yoo HH
Biomed Pharmacother; 2021 Oct; 142():112015. PubMed ID: 34388532
[TBL] [Abstract][Full Text] [Related]
5. Application of Nanotechnology in the COVID-19 Pandemic.
Yang D
Int J Nanomedicine; 2021; 16():623-649. PubMed ID: 33531805
[TBL] [Abstract][Full Text] [Related]
6. Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.
Rana MM
J Biomater Sci Polym Ed; 2021 Jun; 32(9):1219-1249. PubMed ID: 33787467
[TBL] [Abstract][Full Text] [Related]
7. The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S; Shariati L; Boshtam M; Rahimmanesh I; Mirian M; Esmaeili Y; Najaflu M; Khanahmad N; Zeinalian M; Trovato M; Tay FR; Khanahmad H; Makvandi P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064039
[TBL] [Abstract][Full Text] [Related]
8. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
Tammam SN; El Safy S; Ramadan S; Arjune S; Krakor E; Mathur S
J Control Release; 2021 Sep; 337():258-284. PubMed ID: 34293319
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Infection: Targeting Possibilities for Treatment.
Haider T; Gour V; Pandey V; Kanwar IL; Tiwari R; Vishwakarma M; Bakshi AK; Sarkar A; Yadav R; Soni S; Soni V
Crit Rev Ther Drug Carrier Syst; 2021; 38(3):75-115. PubMed ID: 34348019
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.
Mirtaleb MS; Mirtaleb AH; Nosrati H; Heshmatnia J; Falak R; Zolfaghari Emameh R
Biomed Pharmacother; 2021 Jun; 138():111518. PubMed ID: 33774315
[TBL] [Abstract][Full Text] [Related]
11. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
Gudadappanavar AM; Benni J
J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
[TBL] [Abstract][Full Text] [Related]
13. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
Bhattacharyya P; Das S; Aich S; Sarkar J
Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
[TBL] [Abstract][Full Text] [Related]
14. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
Edwards AM; Baric RS; Saphire EO; Ulmer JB
Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Discovery, diagnostics and drug development.
Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
[TBL] [Abstract][Full Text] [Related]
16. Review: An insight into coronaviruses: Challenges, security and scope.
Shah N; Davariya V; Gupta SK; Gajjar P; Parmar J; D'Cruz L
Rev Med Virol; 2020 Nov; 30(6):1-8. PubMed ID: 32754974
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
19. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
Majumder J; Minko T
AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
[TBL] [Abstract][Full Text] [Related]
20. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
